Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 11, 2016, Pages 1593-1601.e2

  Amiot, Aurelien ^a,y   Grimaud, Jean Charles ^b,y   Peyrin Biroulet, Laurent ^c,y   Filippi, Jerome ^d,y   Pariente, Benjamin ^e,y   Roblin, Xavier ^f,y   Buisson, Anthony ^g,y   Stefanescu, Carmen ^h,y   Trang Poisson, Caroline ^i,y   Altwegg, Romain ^j,y   Marteau, Philippe ^k,y   Vaysse, Thibaud ^l   Bourrier, Anne ^m   Nancey, Stephane ^n,y   Laharie, David ^o,y   Allez, Matthieu ^p,y   Savoye, Guillaume ^q,y   Moreau, Jacques ^r,y   Gagniere, Charlotte ^a,y   Vuitton, Lucine ^s,y   Viennot, Stephanie ^t,y   Aubourg, Alexandre ^u,y   Pelletier, Anne Laure ^v,y   Bouguen, Guillaume ^w,y   Abitbol, Vered ^x,y   Bouhnik, Yoram ^h,y   Zallot, Camille ^y   Bigard, Marc Andre ^y   Hebuterne, Xavier ^y   Nachury, Maria ^y   Desreumaux, Pierre ^y   Del Tedesco, Emilie ^y   Bommelaer, Gilles ^y   Boureille, Arnaud ^y   Dray, Xavier ^y   Carbonnel, Franck ^y   Seksik, Philippe ^y   Beaugerie, Laurent ^y   Cosnes, Jacques ^y   Sokol, Harry ^y   Landman, Cecilia ^y   Boschetti, Gilles ^y   Poullenot, Florian ^y   Gornet, Jean Marc ^y   Baudry, Clautilde ^y   Koch, Stephane ^y   Picon, Laurence ^y   Sickersen, Gaelle ^y   Chaussade, Stanislas ^y   Nahon, Stephane ^y   Winkfield, Betsy ^y   Brixi Benmansour, Hedia ^y   Gincul, Rodica ^y   Barberis, Jean Christophe ^y   Bonaz, Bruno ^y   Michiels, Christophe ^y   Zerbib, Franck ^y   de Beauregard, Marie Bourrier ^y   Locher, Christophe ^y   Davin Couve, Sophie ^y   Poirette, Armelle ^y   Guillem, Laurence ^y   Stetiu Mocanu, Monica ^y   Beorchia, Sylvain ^y   Al Qaddi, Jawad ^y   more..

^a University of Paris Est Créteil   (France)

^b HÔPITAL NORD   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIV LILLE   (France)

^f UNIVERSITÉ JEAN MONNET   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j HÔPITAL SAINT ELOI   (France)

^k HÔPITAL LARIBOISIÈRE   (France)

^l BICÊTRE HOSPITAL   (France)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ UNIVERSITÉ LYON 1   (France)

^o HAUT LÉVÊQUE HOSPITAL   (France)

^p SAINT LOUIS HOSPITAL   (France)

^q UNIVERSITÉ DE ROUEN   (France)

^r CHU RANGUEIL   (France)

^s UNIVERSITY HOSPITAL OF BESANÇON   (France)

^t CAEN UNIVERSITY HOSPITAL   (France)

^u SERVICE DE DERMATOLOGIE   (France)

^v BICHAT HOSPITAL   (France)

^w UNIVERSITÉ DE RENNES 1   (France)

^x University Paris 5 Descartes ^*  (France)

^y NONE

more..

Author keywords

Cell Adhesion; Drug; IBD; Inhibitor

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; MERCAPTOPURINE; METHOTREXATE; STEROID; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HEALTH CARE ACCESS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFLUENZA; INFUSION RELATED REACTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PHARYNGITIS; PROTEIN BLOOD LEVEL; PRURITUS; RECTUM CARCINOMA; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN DISEASE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; ADOLESCENT; AGED; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84969922547     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.02.016     Document Type: Article

References (21)

1. 1 Amiot, A., Peyrin-Biroulet, L., Currrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol 8 (2015), 66–82.
2. 2 Feagan, B.G., Greenberg, G.R., Wild, G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005), 2499–2507.
3. 3 Fiorino, G., Correale, C., Fries, W., et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol 6 (2010), 567–572.
4. 4 Lobaton, T., Vermeire, S., Van Assche, G., et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 39 (2014), 579–594.
5. 5 Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
6. 6 Sandborn, W.J., Feagan, B.G., Rutgeerts, P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
7. 7 Sands, B.E., Feagan, B.G., Rutgeerts, P., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147 (2014), 618–627.e3.
8. 8 Hézode, C., Fontaine, H., Dorival, C., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147 (2014), 132–142.e4.
9. 9 Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
10. 10 Satsangi, J., Silverberg, M.S., Vermeire, S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
11. 11 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
12. 12 Harvey, R.F., Bradshaw, J.M., A simple index of Crohn's-disease activity. Lancet, 1, 1980, 514.
13. 13 Shelton, E., Allegretti, J.R., Stevens, B., et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis 21 (2015), 2879–2885.
14. 14 Pineton de Chambrun, G., Peyrin-Biroulet, C., Lemann, M., et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7 (2010), 15–29.
15. 15 Dulai, P.S., Siegel, C.A., Colombel, J.-F., et al. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 63 (2014), 1843–1853.
16. 16 Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
17. 17 Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400 e3.
18. 18 Jones, J.L., Kaplan, G.G., Peyrin-Biroulet, L., et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 13 (2015), 2233–2240.
19. 19 Cleynen, I., Vermeire, S., Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 9 (2012), 496–503.
20. 20 Lewis, J.D., Lichtenstein, G.R., Deren, J.J., et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134 (2008), 688–695.
21. 21 Vermeire, S., Schreiber, S., Sandborn, W.J., et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 8 (2010), 357–363.